TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

Methoxyamine hydrochloride (TRC102) has been shown to potentiate the activity of temozolomide by preventing base excision repair (BER) and allowing cleavage of TRC102 bound deoxyribonucleic acid (DNA), which will cause DNA strand breaks in cancer cells. We hypothesize that oral TRC102 can be safely co-administered with Temozolomide (TMZ) and would potentiate DNA damage caused by TMZ resulting in antitumor responses.

CT scans will be performed at baseline, and repeat scans will be performed every 2 cycles (every 3 cycles for participants on study more than one year).

If diarrhea develops and does not have an identifiable cause other than study drug administration, anti-diarrheal's such as Lomotil (diphenoxylate hydrochloride (HCl) 2.5 mg + atropine sulfate 0.025 mg/tablet) dosed according to package insert or loperamide 4 mg by mouth (po) after the first unformed stool with 2 mg po every 2 hours as long as unformed stools continue (4 mg every 4 hours while asleep). No more than 16 mg of loperamide should be taken in during a 24-hour period.

If a participant develops nausea/vomiting, an anti-emetic such as prochlorperazine may be given.

If a participant develops nausea/vomiting, an anti-emetic such as metoclopramide may be given.

If a participant develops nausea/vomiting, an anti-emetic such as 5-HT3 antagonist may be given.

If a participant develops nausea/vomiting, an anti-emetic such as aprepitant may be given.

Tumor biopsies will be optional during the escalation phase.